Combination chemo for relapsed solid tumors in teens
Part of Cancer clinical trials.
This trial tests a new combination of three chemotherapy drugs (irinotecan liposomes, temozolomide, and vincristine) for children and teens with solid tumors that have not responded to or have come back after standard treatment. The goal is to see if this combination can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 18 years old.
- You have a solid tumor (like neuroblastoma or other childhood cancer) that has come back or not responded to standard treatment.
- Your cancer can be seen on scans (like CT or MRI) and is measurable.
- Your heart, kidneys, liver, and blood counts are working well enough (as checked by your doctor).
- You have recovered from any side effects of previous treatments, and it has been enough time since your last therapy.
- You are not pregnant, and you do not have certain infections (like hepatitis B, HIV, or syphilis) or uncontrolled health problems (like high blood pressure, diabetes, or heart disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or not responded to treatment. The goal is to see if this combination can shrink or control the tumor.
This trial tests a new combination of chemotherapy drugs (irinotecan, temozolomide, and vincristine) for children whose solid tumors have come back or not responded to standard treatment. It aims to see if a specific gene test can help doctors choose the right dose of irinotecan to reduce side effects.
This trial tests a new combination of three chemotherapy drugs (eribulin, irinotecan, and temozolomide) for children and young adults whose solid tumors have come back or not responded to standard treatment. The goal is to see if this combination is safe and effective.
This trial compares two treatment combinations—liposomal doxorubicin plus irinotecan versus a different chemotherapy plan—in children and teens whose rhabdomyosarcoma came back or did not respond. It aims to see which option works better and is safer for children who have had prior cancer treatment.
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
This early-phase study tests repotrectinib (a targeted anti-cancer pill) combined with chemotherapy in children and young adults whose solid tumors have come back or did not respond to standard treatment. The goal is to see how safe the treatment is and whether it can shrink tumors.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.